Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438335 | 0.85 | KEAP1 (0.37) | KDM4EATMTAAR1ADRA1ATSHR | |
| SCHEMBL13634487 | 0.79 | PDE4B (0.39) | KDM4ETSHRKMT2APDE10A | |
| SCHEMBL18209493 | 0.77 | CCR1 (0.43) | KDM4ECYP3A4KMT2APDE10A | |
| SCHEMBL23196096 | 0.76 | KDM4E (0.41) | KDM4EATMTAAR1ADRA1ATSHR | |
| SCHEMBL22446798 | 0.74 | KMT2A (0.34) | KDM4EATMCYP1A2CYP3A4KMT2A | |
| SCHEMBL7960097 | 0.71 | KDM4E (0.41) | KDM4ETSHRLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1871955 | 0.70 | KDM4E (0.44) | KDM4ETSHRLMNAMEN1KMT2A | |
| SCHEMBL359862 | 0.70 | MCHR1 (0.50) | KDM4EATMTSHRCYP3A4LMNA | |
| SCHEMBL21082217 | 0.70 | HCRTR1 (0.39) | CYP3A4MEN1KMT2AMAPK1PDE10A | |
| SCHEMBL29108437 | 0.68 | CTSD (0.33) | KDM4ECYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493299-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2451281-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| WO-2011053522-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053522-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | KDM4E 3242/4885ATM 4807/4885TAAR1 111/4885 |
| US-20120196901-A1 | TERTIARY AMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | KDM4E 2007/4885ATM 4633/4885TAAR1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.